INVESTMENTS THAT MATTER

Agent Capital is a healthcare venture capital firm focused on investing in novel, differentiated therapeutics and treatments that address unmet patient needs.

Across all stages of development, we align ourselves with scientists, entrepreneurs and other investors to develop the next generation of healthcare innovations that will have a positive impact on patients’ lives.

OUR PROVEN STRATEGY

At Agent Capital, we proactively guide biotech companies to milestones and exits.

With a balanced investment approach and a deep understanding of biopharma’s pipeline pressures, we are committed to making investments that move healthcare forward – no matter the stage or investment type.

TYPICALLY, OUR KEY INVESTMENT AREAS OF FOCUS INCLUDE:

Rare Diseases
Oncology
Neurology
Immunology
Learn More

Featured Portfolio Company

Dice Therapeutics

Freenome

Metagenomi

Pliant Therapeutics

ViTToria Biotherapeutics

Dragonfly Therapeutics

Carisma Therapeutics

Skyhawk Therapeutics

Flare Therapeutics

ImCheck Therapeutics

Orchard Therapeutics

Entrada Therapeutics

Zenas Biopharma

Star Therapeutics

Pyxis Oncology

Precision Biosciences

Palvella Therapeutics

View Full Portfolio

Featured News

Press Release | May 19, 2026

Dragonfly Therapeutics Announces Encouraging Early Results from the Phase 1 for DF5112, its CCR6-Targeting Molecule

Read More

Press Release | May 12, 2026

Boehringer Ingelheim licenses preclinical antibody program from Immunitas Therapeutics to advance treatments for chronic inflammatory diseases

Read More

Press Release | March 2, 2026

Skyhawk Announces Australia’s Therapeutic Goods Administration Has Determined SKY-0515 for Huntington’s Disease Meets Eligibility Criteria for Registration via the Provisional Approval Pathway

Read More

View All